Commure Raises $70M at $7B — What It Means for RCM

Commure closed $70M this morning at a $7 billion post-money valuation, led by General Catalyst with Sequoia, Morgan Stanley, and Kirkland & Ellis. The claim: 85% of revenue cycle work, no human required. Here's what RCM teams need to know.

$7B

Post-money valuation — one of the largest in healthcare AI. Commure processes tens of billions in annual claims across 500+ health organizations.

What Commure Actually Does

Commure (which absorbed Athelas) runs end-to-end RCM — front, middle, and back — plus an Ambient AI suite that handles autonomous coding and clinical documentation. The platform is embedded inside 130+ of the nation's largest health systems, including HCA Healthcare and Tenet Healthcare, across 3,000+ sites of care and integrates with 60+ EHRs.

The headline stat from the press release: 85%+ of revenue cycle work completed without human intervention. That's the number investors are buying. It covers the calls, the notes, the codes, the claims, the denials, and the appeals — the full cycle, not just one piece of it.

CEO Tanay Tandon's quote cuts right to it: "For thirty years, healthcare was told software would fix administrative work. It didn't, because software could not actually do the work. AI can."

Where the $70M Goes

Three stated uses:

Scale RCM across specialty practices, hospitals, and IDNs — explicitly targeting the legacy BPO and billing vendor market
Advance their agentic AI layer — building systems that handle payer rules, specialty coding, denial patterns, and clinical context that general-purpose models miss
International expansion — same structural problem (workforce shortages, admin burden) exists globally

The BPO angle is the most significant near-term signal. Commure is positioning directly against outsourced billing vendors and rules-based RCM software. At $7B, they have the runway to undercut legacy vendors on price while building market share.

The Signal for RCM Teams

When General Catalyst leads a $70M round at a $7B valuation in RCM AI, it's a market confirmation, not just a company milestone. The bet is that autonomous revenue cycle is real enough, at scale enough, to justify that multiple. That has implications for everyone in the space.

⚠️ Watch: Vendor Consolidation Pressure

Commure's war chest accelerates pressure on mid-market RCM vendors and billing services. If you're evaluating vendors in 2026, ask any finalist directly: how does your platform compete with Commure's autonomous workflow claims?

For health systems already on Commure or Athelas: this funding extends their runway and accelerates product development on the agentic side. The integration roadmap matters — particularly how their specialty coding handles edge cases where the 15% human-in-the-loop kicks in.

For everyone else: this is a benchmark. The bar for what "AI-enabled RCM" means just moved. 85% autonomous isn't a marketing claim anymore — it's the number your next vendor evaluation has to address.

Bottom Line

Commure just became one of the best-capitalized independent RCM AI platforms in the country. The $7B valuation is a bet that autonomous revenue cycle replaces most of what BPO vendors and legacy billing software do today. The timeline is compressed. If you're not benchmarking your current stack against what Commure claims to do, you're already behind the evaluation cycle.